Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED
平安健康醫療科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1833)

RENEWAL OF CONTINUING CONNECTED TRANSACTIONS AND A MAJOR TRANSACTION ENTERING INTO OF THE 2026 FRAMEWORK AGREEMENTS

Reference is made to the announcement of Ping An Healthcare and Technology Company Limited (the "**Company**") dated 28 September 2026 (the "**Announcement**"), in relation to the Company proposing to enter into the 2026 Provision of Products and Services Framework Agreement, the 2026 Services Purchasing Framework Agreement, the 2026 Financial Service Cooperation Framework Agreement, the 2026 Property Leasing Framework Agreement, the 2026 Provision of Products and Services Framework Agreement with Life Insurance and the 2026 Services Purchasing Framework Agreement with Life Insurance, to renew the 2023 Provision of Products and Services Framework Agreement, the 2023 Services Purchasing Framework Agreement, the 2023 Financial Service Framework Agreement and the 2023 Property Leasing Framework Agreement. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The transactions contemplated under each of (i) the 2026 Provision of Products and Services Framework Agreement, (ii) the 2026 Services Purchasing Framework Agreement, (iii) the 2026 Financial Service Cooperation Framework Agreement, (iv) the 2026 Property Leasing Framework Agreement, (v) the 2026 Provision of Products and Services Framework Agreement with Life Insurance, and (vi) the 2026 Services Purchasing Framework Agreement with Life Insurance constitute continuing connected transactions of the Company pursuant to Chapter 14A of the Listing Rules. The wealth management services and derivative services under the 2026 Financial Service Cooperation Framework Agreement constitute a major transaction of the Company under Chapter 14 of the Listing Rules.

The Board announces that the Company has entered into with the relevant parties the 2026 Provision of Products and Services Framework Agreement on 9 November 2026, the 2026 Services Purchasing Framework Agreement on 9 November 2026, the 2026 Financial Service Cooperation Framework Agreement on 9 November 2026, the 2026 Property Leasing Framework Agreement on 9 November 2026, the 2026 Provision of Products and Services Framework Agreement with Life Insurance on 16 October 2026 and the 2026 Services Purchasing Framework Agreement with Life Insurance on 16 October 2026, respectively.

There have been no material changes in the principal terms of the aforesaid 2026 framework agreements entered into as compared with those set out in the Announcement. Furthermore, the Directors (for the purpose of the 2026 Provision of Products and Services Framework Agreement, the 2026 Services Purchasing Framework Agreement, the 2026 Financial Service Cooperation Framework Agreement and the 2026 Provision of Products and Services Framework Agreement with Life Insurance, other than the independent non-executive Directors, whose opinions are set out in the circular published by the Company on 9 November 2026) remain of the view that the terms of the aforesaid 2026 framework agreements were determined after arm's length negotiations, and the respective transactions contemplated thereunder are entered into in the ordinary and usual course of business of the Group and on normal commercial terms, are fair and reasonable, and are in the interests of the Company and its Shareholders as a whole.

By order of the Board
Ping An Healthcare and Technology Company Limited
Mr. Yougang Zhu
Chairman

Shanghai, the PRC
9 November 2026

As at the date of this announcement, the Board comprises Mr. Mingke He and Mr. Tongzhuan Xi as executive Directors; Mr. Yougang Zhu and Ms. Yanjun Fan as non-executive Directors; and Mr. Yunwei Tang, Mr. Tianyong Guo and Dr. Kwok Tung Donald Li as independent non-executive Directors.